<DOC>
	<DOCNO>NCT01814904</DOCNO>
	<brief_summary>The Primary Objective study determine initial start dos colestilan ( MCI-196 ) paediatric subject Chronic Kidney Disease Stage 5 Dialysis Hyperphosphataemia .</brief_summary>
	<brief_title>Dose-finding Study MCI-196</brief_title>
	<detailed_description>This study terminate insufficient patient recruitment . There safety concern .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Bile Acids Salts</mesh_term>
	<criteria>Children age 2 year &lt; 18 year CKD stage 5 dialysis ( haemodialysis peritoneal dialysis ) least one month The subject document diagnosis hyperphosphataemia , demonstrate serum phosphorus ( P ) level agerelated upper limit normal KDOQI Clinical Practice Guidelines Nutrition Children CKD updated 2008 ) The subject take CBPB prior enrolment study ( i.e. , prior screen visit ) The subject must demonstrate serum P level &gt; 1.5 standard deviation ( SD ) KDOQI 2008 agerelated mean value time washout period ( must demonstrate stop treatment CBPB ) At time randomisation , subject must demonstrate increase serum P level his/her recent P central laboratory measurement least 10 % prewashout level The subject diagnose hypocholesterolaemia ( i.e. , cholesterol level agerelated normal range , per local practice ) The subject current clinically significant medical comorbidities , may substantially compromise subject safety , expose him/her undue risk , interfere significantly study procedure , opinion Investigator , make subject unsuitable inclusion study ( e.g. , subject currently history seizure disorder , dysphagia , swallow disorder , predisposition current bowel obstruction , ileus severe gastrointestinal [ GI ] disorder chronic severe constipation [ judge Investigator ] , intestinal stenosis , intestinal diverticulum , sigmoid colitis , GI ulcer , current history GI bleeding , major GI tract surgery ) The subject treat combination two phosphate binder within one month prior screen The subject stop treatment ( prescription overthe counter ) follow orally take medication washout period : product contain calcium ( Ca ) , magnesium ( Mg ) , aluminium compound , sevelamer , lanthanum , ketosteril The subject receive immunosuppressant treatment medical condition time randomisation expect receive treatment course study The subject consider unstable his/her current treatment CKD within one month prior screen ( e.g. , subject start treatment vitamin D analogue , agents/procedures may influence bone mineral metabolism [ i.e. , serum P Ca level ] )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>